Cell-specific, promoter-dependent mineralocorticoid agonist activity of spironolactone

Molecular Pharmacology

Volumn 51, Issue 2, 1997, Pages 285-292

  Massaad, Charbel ^a   Lombès, Marc ^b   Aggerbeck, Martine ^a   Rafestin Oblin, Marie Edith ^b   Barouki, Robert ^a  

^a HENRI MONDOR HOSPITAL   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7ALPHA PROPYLSPIRONOLACTONE; ALDOSTERONE; CYCLIC AMP; CYPROTERONE ACETATE; MIFEPRISTONE; MINERALOCORTICOID ANTAGONIST; MINERALOCORTICOID RECEPTOR; PROGESTERONE; SPIRONOLACTONE;

ARTICLE; CELL SPECIFICITY; CONTROLLED STUDY; DRUG MECHANISM; FIBROBLAST CULTURE; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 0031034423     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.51.2.285     Document Type: Article

References (40)

1. Evans, R. M. The steroid and thyroid hormone receptor superfamily. Science (Washington D. C.) 240:889-294 (1988).
2. Raynaud, J. P., and T. Ojasoo. The design and use of sex-steroid antagonists. J. Steroid Biochem. 25:811-833 (1986).
3. Baulieu, E. E. The antisteroid RU 486: its cellular and molecular mode of action. Trends Endocrinol. Metab. 2:233-239 (1991).
4. Beck, C. A., N. L. Wiegel, M. L. Moyer, S. K, Nordeen, and D. P. Edwards. The progesterone antagonist RU 486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc. Natl. Acad. Sci. USA 90:4441-4445 (1993).
5. Green, S., and P. Chambon. The oestrogen receptor: from perception to mechanism, in Nuclear Hormone Receptors (M. G. Parker, ed.). Academic Press, London, 15-38 (1991).
6. Corvol, P., M. Claire, M. E. Oblin, K. Geering, and B. Rossier. Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int. 20:1-6 (1981).
7. Skluth, H. A., and J. G. Gums. Spironolactone: a re-examination. DICP Ann. Pharmacother. 24:52-59 (1991).
8. Lombès, M., N. Binart, M. E. Oblin, V. Joulin, and E. E. Baulieu. Characterization of the interaction of the human mineralocorticoid receptor with hormone response elements. Biochem. J. 292:577-583 (1993).
9. Binart, N., M. Lombès, M. E. Rafestin-Oblin, and E. E. Baulieu. Characterization of human mineralocorticoid receptor expressed in the baculovirus system. Proc. Natl. Acad. Sci. USA 88:10681-10685 (1991).
10. Funder, J. W. Mineralocorticoids, glucocorticoids, receptors and response elements. Science (Washington D. C.) 259:1132-1133 (1993).
11. Trapp, T., and F. Holsboer. Ligand-induced conformational changes in the mineralocorticoid receptor analyzed by protease mapping. Biochem. Biophys. Res. Commun. 215:286-291 (1995).
12. Couette, B., M. Lombès, E. E. Baulieu, and M. E. Rafestin-Oblin. Aldosterone antagonists destabilize the mineralocorticoid receptor. Biochem. J. 282:697-702 (1992).
13. Couette, B., J. Fagart, S. Jalaguier, M. Lombès, A. Souque, and M. E. Rafestin-Oblin. Ligand-induced conformational change in the human mineralocorticoid receptor occurs within its hetero-oligomeric structure. Biochem. J. 315:421-427 (1996).
14. Lombès, M., N. Binart, F. Delahaye, E. E. Baulieu, and M. E. Rafestin-Oblin. Differential intracellular localization of human mineralocorticoid receptor on binding of agonists and antagonists. Biochem. J. 302:191-197 (1994).
15. Knowles, B. B., C. D. Howe, and D. P. Aden. Human hepatocellular carcinoma cell lines secrete the major plasma proteins and hepatitis B surface antigen. Science (Washington D. C.) 209:497-499 (1980).
16. Prié, D., G. Freidland, C. Coureau, A. Vandewalle, R. Cassingena, and P. Ronco. Role of adenosine on glucagon-induced cAMP in a human cortical collecting duct cell line. Kidney Int. 47:1310-18 (1995).
17. Arriza, J. L., C. Weinberger, G. Cerelli, T. M. Glasser, B. L. Handelin, D. E. Housman, and R. M. Evans. Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science (Washington D. C.) 237:268-275 (1987).
18. Umesono, K., V. Giguere, C. K. Glass, M. G. Rosenfeld, and R. M. Evans. Retinoic acid and thyroid hormone induce gene expression through a common responsive element. Nature (Lond.) 336:262-265 (1988).
19. Garlatti, M., M. Daheshia, E. Slater, J. Bouguet, M. Beato, and R. Barouki. A functional glucocorticoid responsive unit constituted of two overlapping inactive glucocorticoid responsive element: evidence for a glucocorticoid receptor tetramer formation. Mol. Cell. Biol. 14:8007-8017 (1994).
20. Garlatti, M., V. Tchesnokov, M. Daheshia, S. Feilleux-Duché, J. Hanoune, M. Aggerbeck, and R. Barouki. CCAAT/enhancer-binding protein-related proteins bind to the unusual promoter of the aspartate aminotransferase housekeeping gene. J. Biol. Chem. 568:6567-6574 (1993).
21. Moyer, M. L., K. C. Borror, B. J. Bona, D. B. DeFranco, and S. K. Nordeen. Modulation of cell signaling pathways can enhance or impair glucocorticoid-induced gene expression without altering the state of receptor phosphorylation. J. Biol. Chem. 268:22933-22940 (1993).
22. Aggerbeck, M., M. Garlatti, S. Feilleux-Duché, C. Veyssier, M. Daheshia, J. Hanoune, and R. Barouki. Regulation of the cytosolic aspartate aminotransferase housekeeping gene promoter by glucocorticoids, cAMP, and insulin. Biochemistry 32:9065-9072 (1993).
23. Jiang, S. Y., D. M. Wolf, J. M. Yingling, C. Chang, and V. C. Jordan. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol. Mol. Cell. Endocrinol. 90:77-86 (1992).
24. De Wet, J. R., K. V. Wood, M. Deluca, D. R. Helsinki, and S. Subramani. Firefly luciferase gene: structure and expression in mammalian cells. Mol. Cell. Biol. 7:725-737 (1987).
25. Neumann, J. R., C. A. Morency, and K. O. Russian. A novel rapid assay for chloramphenicol acetyltransferase gene expression. Biotechniques 5:444-448 (1987).
26. Trapp, T, R. Rupprecht, M. Castrén, J. Reul, and F. Holsboer. Heterodimerization between mineralocorticoid and glucocorticoid receptor: a new principle of glucocorticoid action in the CNS. Neuron 13:1457-1462 (1994).
27. Meyer, M. E., Pornon A, J. Ji, M. T. Bocquel, P. Chambon, and H. Gronemeyer. Agonistic and antagonistic activities of RU 486 on the functions of the human progesterone receptor. EMBO J. 9:3923-3932 (1990).
28. Nordeen, S. K., B. J. Bona, and M. L. Moyer. Latent agonist activity of the steroid antagonist, RU 486, is unmasked in cells treated with activators of protein kinase A. Mol. Endocrinol. 7:731-742 (1993).
29. Fujimoto, N., and B. S. Katzenellenbogen. Alteration in the agonist/ antagonist balance of antiestrogens by activation of protein kinase A signaling pathways in breast cancer cells: antiestrogen selectivity and promoter dependence. Mol. Endocrinol. 8:296-304 (1994).
30. McDonnell, D. P, D. L. Clemm, T. Hermann, M. E. Goldman, and J. W. Pike. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol. Endocrinol. 9:659-669 (1995).
31. Sakauye, C., and D. Feldman. Agonist and anti-mineralocorticoid activities of spirolactones. Am. J. Physiol. 231:93-97 (1976).
32. Rupprecht, R., J. M. H Reul, B. Steensel, D. Spengler, M. Söder, B. Berning, F. Holsboer, and K. Damm. Pharmacological and functional characterization of human mineralocorticoid receptor. Eur. J. Pharmacol. 247:145-154 (1993).
33. Nordeen, S. K., B. J. Bona, C. A. Beck, D. P. Edwards, K. C. Borror, and D. B. DeFranco. The two faces of a steroid antagonist: when an antagonist isn't. Steroids 60:97-104 (1995).
34. Fanestil, D. Mechanism of action of aldosterone blockers. Semin. Nephrol. 8:249-263 (1988).
35. Bonvalet, J. P., M. Blot-Chabaud, and N. Farman. Autoradiographic evidence of nuclear binding of spironolactone in rabbit cortical collecting tubule. Endocrinology 128:280-284 (1991).
36. Robertson, N. M., G. Schulman, S. Karnik, E. Alnemri, and G. Litwack. Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using an anti-MR antibody and confocal laser scanning microscopy. Mol. Endocrinol. 7:1226-1239 (1993).
37. Webster, N., S. Green, J. R. Jin, and P. Chambon. The hormone-binding domains of the estrogen and glucocorticoid receptors contain an inducible transcription activation function. Cell 54:199-207 (1988).
38. Tora, L., J. White, C. Brou, D. Tasset, N. Webster, E. Scheer, and P. Chambon. The human estrogen receptor has two independent nonacidic transcriptional activation functions. Cell 59:477-487 (1989).
39. Anolik, J., C. Klinge, R. Hilf, and R. Bambara. Cooperative binding of estrogen receptor to DNA depends on spacing of binding sites, flanking sequence, and ligand. Biochemistry 34:2511-2520 (1995).
40. Rupprecht, R., J. L. Arriza, D. Spengler, J. Reul, R. M. Evans, F. Holsboer, and K. Damm. Transactivation and synergistic properties of the mineralocorticoid receptor: relationship to the glucocorticoid receptor. Mol. Endocrinol. 7:597-602 (1993.).